Evidence map›Paper›PMID 34206017›Full record

ArticleAntioxidants (Basel, Switzerland)2021

Immunological Aspects of X-Linked Chronic Granulomatous Disease Female Carriers.

Maria Chiriaco, Irene Salfa, Giorgiana Madalina Ursu, Cristina Cifaldi, Silvia Di Cesare, Paolo Rossi, Gigliola Di Matteo, Andrea Finocchi

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. How I Treat: Chronic granulomatous disease.Journal of human immunity · 2026
    Review
  2. Review
  3. Article
  4. The Role of NADPH Oxidase 2 in Leukocytes.Antioxidants (Basel, Switzerland) · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Maria ChiriacoDepartment of Systems Medicine, University of Rome Tor Vergata, via Montpellier 1, 00133 Rome, Italy.
Irene SalfaResearch Unit of Primary Immunodeficiency, Academic Department of Pediatrics, Immune and Infectious Diseases Division, Bambino Gesù Children Hospital, Piazza S. Onofrio 4, 00165 Rome, Italy.
Giorgiana Madalina UrsuDepartment of Systems Medicine, University of Rome Tor Vergata, via Montpellier 1, 00133 Rome, Italy.
Cristina CifaldiResearch Unit of Primary Immunodeficiency, Academic Department of Pediatrics, Immune and Infectious Diseases Division, Bambino Gesù Children Hospital, Piazza S. Onofrio 4, 00165 Rome, Italy.
Silvia Di CesareDepartment of Systems Medicine, University of Rome Tor Vergata, via Montpellier 1, 00133 Rome, Italy.
Paolo RossiDepartment of Systems Medicine, University of Rome Tor Vergata, via Montpellier 1, 00133 Rome, Italy.
Gigliola Di MatteoDepartment of Systems Medicine, University of Rome Tor Vergata, via Montpellier 1, 00133 Rome, Italy.
Andrea FinocchiDepartment of Systems Medicine, University of Rome Tor Vergata, via Montpellier 1, 00133 Rome, Italy.
Bambino Gesù Children's Hospital · ITUniversity of Rome Tor Vergata · IT

Funding

Childrens' Hospital Bambino Gesù RICERCA CORRENTE 2019European Joint Programme on Rare Diseases CELL-PID HEALTH F5-2010-261387European research projects on rare diseases' ERARE_EURO CGD 2009Italian Telethon Foundation GGP15109
6 · The paper itself

Abstract

X-linked Granulomatous Disease (XL-CGD) carriers were previously thought to be clinically healthy because random X-chromosome inactivation (XCI) allows approximately half of their phagocytes/monocytes to express functional gp91phox protein. This supports the NADPH oxidase activity necessary for the killing of engulfed pathogens. Some XL-CGD carriers suffer from inflammatory and autoimmune manifestations as well as infections, although the skewed-XCI of a mutated allele is reported to be exclusively determinant for infection susceptibility. Indeed, immune dysregulation could be determined by dysfunctional non-phagocytic leukocytes rather than the percentage of functioning neutrophils. Here we investigated in a cohort of 12 X-CGD female carriers at a particular time of their life the gp91phox protein expression/function and how this affects immune cell function. We showed that 50% of carriers have an age-independent skewed-XCI and 65% of them have a misrepresented expression of the wild-type gene. The majority of carriers manifested immune dysregulation and GI manifestations regardless of age and XCI. Immunological investigations revealed an increase in CD19+ B cells, CD56bright-NK cell percentage, a slightly altered CD107a upregulation on CD4+ T cells, and reduced INFγ-production by CD4+ and CD8+ cells. Notably, we demonstrated that the residual level of ROS robustly correlates with INFγ-expressing T cells, suggesting a role in promoting immune dysregulation in carriers.

Indexed as

chronic granulomatous disease (CGD)dihydrorhodamine (DHR) assayimmune dysregulationnicotinamide dinucleotide phosphate oxidase (NADPH)reactive oxygen species (ROSs)X-chromosome inactivation (XCI)X-linked CGD carrier

Identifiers

PMID34206017
PMCPMC8229314
OpenAlexW3169098559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.